To the full analysis
CSPC Pharmaceutical Group stock: growth
1093.HKCSPC Pharmaceutical Group reported $3.8B in revenue for fiscal 2025, down 14.2% on the prior year, up 1.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
10.9%
per year from 2006 to 2025, per share 3.3%
Earnings (Annual rate)
33.5%
per year from 2006 to 2025, per share 24.3%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 1.4% | 10.3% | 10.9% |
| Revenue per share | 2.4% | 10.2% | 3.3% |
| Earnings | −5.0% | 10.5% | 33.5% |
| Earnings per share | −4.2% | 10.6% | 24.3% |
| Free cash flow | −4.3% | 12.9% | no data |
| Free cash flow per share | −3.4% | 12.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $529.08M | $2.34M | −$15.82M |
| 2007 | $700.63M | $67.08M | $36.77M |
| 2008 | $934.79M | $141.05M | $145.7M |
| 2009 | $927.95M | $128.11M | $112.86M |
| 2010 | $989.08M | $95.63M | $33.18M |
| 2011 | $295.22M | $43.58M | −$63.63M |
| 2012 | $500.55M | $261.02M | $35.85M |
| 2013 | $1.19B | $145.88M | $19.63M |
| 2014 | $1.29B | $149.89M | $149.88M |
| 2015 | $1.43B | $208.96M | $178.3M |
| 2016 | $1.66B | $282.18M | $232.34M |
| 2017 | $1.96B | $350.51M | $259.21M |
| 2018 | $2.77B | $480.92M | $257.27M |
| 2019 | $2.92B | $489.98M | $272.17M |
| 2020 | $3.54B | $731.53M | $745.44M |
| 2021 | $4.11B | $826.68M | $431.62M |
| 2022 | $4.74B | $932.78M | $993.14M |
| 2023 | $4.72B | $881.36M | $342.78M |
| 2024 | $4.43B | $660.93M | $261.38M |
| 2025 | $3.8B | $567.11M | $598.08M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.